Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

December 1, 2025

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

Methotrexate

Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration

DRUG

Blinatumomab

Blinatumomab 28ug/day continuous infusion for 4 weeks

Trial Locations (1)

RECRUITING

Northside Hospital, Atlanta

All Listed Sponsors

lead

Northside Hospital, Inc.

OTHER